Stock comparison
Boston Scientific
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BSX
Boston Scientific
Market cap
$85.88B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BSX | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 77B | LMAT |
| Benjamin Graham | 69B | 89A | LMAT |
| Philip Fisher | 70C | 81C | LMAT |
| Peter Lynch | 58C | 67B | LMAT |
| Joel Greenblatt | 44D | 56D | LMAT |
| Charlie Munger | 54D | 68D | LMAT |
| Terry Smith | 59D | 69D | LMAT |
Side-by-side metrics
| Metric | BSX | LMAT |
|---|---|---|
| Market cap | $85.88B | $2.23B |
| P/E (TTM) | 22.0x | 37.1x |
| EV/EBIT | 22.1x | 36.6x |
| ROIC (TTM) | 9.9% | 9.43% |
| Gross margin | 70.41% | 72.39% |
| Net margin | 17.24% | 24.35% |
| Revenue CAGR 5y | 13.99% | 12.75% |
| EPS CAGR 5y | 29.71% | 19.04% |
| Debt / Equity | 0.4x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BSX leads on
- Market cap$85.88Bvs $2.23B+97%
- P/E (TTM)22.0xvs 37.1x+41%
- EV/EBIT22.1xvs 36.6x+40%
- EPS CAGR 5y29.71%vs 19.04%+36%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 17.24%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.